Phosphosignature Predicts Dasatinib Response in Non-small Cell Lung Cancer

Targeted drugs are less toxic than traditional chemotherapeutic therapies; however, the proportion of patients that benefit from these drugs is often smaller. A marker that confidently predicts patient response to a specific therapy would allow an individual therapy selection most likely to benefit the patient. Here, we used quantitative mass spectrometry to globally profile the basal phosphoproteome of a panel of non-small cell lung cancer cell lines. The effect of the kinase inhibitor dasatinib on cellular growth was tested against the same panel. From the phosphoproteome profiles, we identified 58 phosphorylation sites, which consistently differ between sensitive and resistant cell lines. Many of the corresponding proteins are involved in cell adhesion and cytoskeleton organization. We showed that a signature of only 12 phosphorylation sites is sufficient to accurately predict dasatinib sensitivity. Four of the phosphorylation sites belong to integrin β4, a protein that mediates cell-matrix or cell-cell adhesion. The signature was validated in cross-validation and label switch experiments and in six independently profiled breast cancer cell lines. The study supports that the phosphorylation of integrin β4, as well as eight further proteins comprising the signature, are candidate biomarkers for predicting response to dasatinib in solid tumors. Furthermore, our results show that identifying predictive phosphorylation signatures from global, quantitative phosphoproteomic data is possible and can open a new path to discovering molecular markers for response prediction. Targeted drugs are less toxic than traditional chemotherapeutic therapies; however, the proportion of patients that benefit from these drugs is often smaller. A marker that confidently predicts patient response to a specific therapy would allow an individual therapy selection most likely to benefit the patient. Here, we used quantitative mass spectrometry to globally profile the basal phosphoproteome of a panel of non-small cell lung cancer cell lines. The effect of the kinase inhibitor dasatinib on cellular growth was tested against the same panel. From the phosphoproteome profiles, we identified 58 phosphorylation sites, which consistently differ between sensitive and resistant cell lines. Many of the corresponding proteins are involved in cell adhesion and cytoskeleton organization. We showed that a signature of only 12 phosphorylation sites is sufficient to accurately predict dasatinib sensitivity. Four of the phosphorylation sites belong to integrin β4, a protein that mediates cell-matrix or cell-cell adhesion. The signature was validated in cross-validation and label switch experiments and in six independently profiled breast cancer cell lines. The study supports that the phosphorylation of integrin β4, as well as eight further proteins comprising the signature, are candidate biomarkers for predicting response to dasatinib in solid tumors. Furthermore, our results show that identifying predictive phosphorylation signatures from global, quantitative phosphoproteomic data is possible and can open a new path to discovering molecular markers for response prediction. The introduction of targeted drugs for treating cancer is a major biomedical achievement of the past decade (1Katzel J.A. Fanucchi M.P. Li Z. Recent advances of novel targeted therapy in non-small cell lung cancer.J. Hematol. Oncol. 2009; 2: 2Crossref PubMed Scopus (58) for cancer PubMed Scopus these drugs molecular that are in are and less toxic than traditional cancer patients benefit from a specific targeted predictive molecular markers are to confidently predict patient response to a specific markers would therapy the therapy is on the molecular profile of the patient. used in the are on marker that is often to the A well for a predictive is or in to predict the response to therapy J.A. and protein in breast study of the and of in breast cancer that for Oncol. PubMed in the or of the or markers sufficient to predict a to molecular signatures comprising markers for response on of candidate molecular markers predicting in solid to for patient PubMed Scopus Li to of patients cancer.J. Oncol. PubMed Scopus our study identified a signature from phosphoproteomic Recent advances in mass for proteins or and for data the of mass to phosphorylation in a and sensitive and to and the phosphorylation sites a in and phosphorylation in PubMed Scopus and quantitative and 2009; PubMed Scopus of PubMed Scopus are in are from the cell to the in these are for the of as and kinase PubMed Scopus as molecular for From molecular to PubMed Scopus and from lung cancer in in of cancer and in in PubMed Scopus for of cancer in of lung cancer are non-small cell lung cancer used the cell lung in cell of and used the cell lung in cell of and PubMed Scopus is a inhibitor the kinase and growth Z. for quantitative protein in cell 2009; PubMed Scopus of of kinase PubMed Scopus is for and dasatinib was in patients only response and 12 kinase and predict the response to dasatinib study of dasatinib in patients lung cancer.J. Oncol. PubMed Scopus the cross-validation non-small cell lung cancer in cell of and the cross-validation non-small cell lung cancer in cell of and study we to a signature of protein phosphorylation that predicts the response to dasatinib in cell lines. cell tested for response to The cell profiled in a global, and the phosphoproteome used to a signature of 12 phosphorylation We the of signature in a cross-validation and the of the predictive we the predictive of the signature in an of breast cancer cell lines. a Li of biomarkers for targeted 2: PubMed Scopus identified phosphorylation sites predicting response to study in from the study the on the and against corresponding we an the involved to the the of phosphorylation sites in sensitive cell and the of to response basal phosphorylation in a panel of cell lines. Here, we the basal phosphoproteome of a panel of sensitive and resistant cell lines. on the growth of dasatinib on a panel of cell in of Li of non-small cell lung on 2009; PubMed Scopus cell and cell from from the and the for The six breast cancer cell from of the cell in and The for the of the cell was in cell in cell as a and to PubMed Scopus The in and and and or and or and from The for a of six to an for the of cell as a from from the and from for The cell in the of and The of cell and 12 of protein of the cell for dasatinib was the cellular of the The in in the of dasatinib a between and The data from the was used to the the was the of the which only growth was from experiments on and data and the of growth data from a the of the A was to a to and the The of the cell the in Li of non-small cell lung on 2009; PubMed Scopus the between the was on a cell showed the to between sensitive and resistant to a of cell resistant in Li of non-small cell lung on 2009; PubMed Scopus sensitive in and sensitive in Li of non-small cell lung on 2009; PubMed Scopus resistant in these cell from the that a predictive and cell in or and the on the the of inhibitor inhibitor cell was and the protein was protein of the cell and a and cell protein as in and to and for to of was for a was the of of The the of to a of and The and a of and the was in of A and a an a The a to A of the to the of the was in of and The and the in and to the to mass was The was an on a a of The a from to of a of and a or mass a of a The mass was in the and a switch between and mass in the the mass was in the a or and a of The most in the for in the a of The in the of the was on and that for for for further The mass data the mass and protein PubMed Scopus the for and protein The was used comprising the The was to was as and sites of was as a protein and phosphorylation of and as the corresponding of and The mass of and was to and mass A of was for proteins and and a or to for was The results to the of quantitative data in the Scopus for further from the the data for identifying a predictive in specific and The of a is as of the between cell and the which used in are that for the of and of a and that the and to Furthermore, sites that are as or that to further The and data on the sites, as well as the of the are in the a was to phosphorylation sites between sensitive and resistant cell lines. only in of the experiments in of sensitive and of resistant data to the the for the A and to proteins phosphorylation sites are in J.A. The and PubMed or of and PubMed Scopus From to in the study of PubMed Scopus was a which for of proteins in a the phosphorylation sites to and the was to for a possible in the of The was the and the data in a the was from phosphoproteomic phosphoproteomic data data a are a and on the A to in PubMed Scopus The A on proteins and in 2009; PubMed Scopus was used as for was to only a than The to and and an than as for the phosphorylation between sensitive and resistant cell to the of experiments in the are and was to the was from eight experiments that was the the as in from phosphoproteomic and the The data was data of cell and the the data of the cell lines. The was used for a and the for the cell that the cell was used for of the cross-validation data and A was only as a data in of the experiments in the data from sensitive and cell and data to the the to the further that the in and the and was and the from the was only to the the data as the was data can the of the corresponding was which is an of the that the the is between the which on the a in the selection for cancer selection PubMed Scopus was the often of that a in The of the is that the the data is of the data the of sensitive and resistant cell and from the to The is to and a of is The of and in to the used to and the and the and the can the of a of and the and data to only a The can to the an a that the between and the the The of was used the the was the the of the data was the The of is the of the to of the the data is to the the less the The the was and the cross-validation the the of a was the the of sensitive likely for a to as to the that is as which that resistant and that the resistant are the and sensitive The is the is the resistant can the of the and and the the of the for an the of a is to from a of the a of the data the the cross-validation was The and for of the and used for the selection of the the of in of the experiments and a of of from which are to for the of the corresponding eight was and used as an the from the of to used for the of the of was in a is the same as the in the the cross-validation we the a the the the of for in the a the corresponding the and a the of in the that to selection of the is the of that to The for the of was the of the in the and to a of and the the of that to the of the that the was as which was the was the and the of the The of the of was in and the 12 the in sites of the of the on which the was that the was of the cross-validation of between sensitive and resistant of the was the 12 of the in the the the inhibitor protein protein inhibitor protein protein of the on which the was that the was The of the cross-validation of between sensitive and resistant The of the was the 12 The of the in the the the in a new The 12 used to the these to The the and which is for the of a the can the in the We used the of and for in the data for the we the same as and the for the The in these are only a on the predictive and was and can to the of new protein in lung cancer cell from cell of protein was on for the of integrin or on for the of protein The proteins to and the in of the used in and as a for the of integrin or for the of and or for the of The the on the growth of dasatinib Li of non-small cell lung on 2009; PubMed Scopus sensitive and resistant cell these cell we to the We the as that on the the cell to sensitive and resistant of cell the was cell the on the from that Li of non-small cell lung on 2009; PubMed Scopus only the cell for which the in we the of the cell and the of the predictive The cell from the for The cell sensitive and used to a predictive The dasatinib in a in patients was study of dasatinib in patients lung cancer.J. Oncol. PubMed Scopus The corresponding is the only the of cell and are than the the cell to we sensitive and resistant cell in cell in cell as a and to PubMed Scopus The sensitive cell in the of and the resistant cell in for A for quantitative of PubMed Scopus was protein of cell in The as a protein of the a sensitive cell and a resistant cell and to a global, quantitative and for identified in the profiled cell lines. of phosphorylation sites a cell to which for of phosphorylation between the cell lines. From the identified phosphorylation sites, as sites, sites that identified in and phosphorylation in PubMed Scopus these sites used in the The of the and is to the in and phosphorylation in PubMed Scopus We to proteins that are between the sensitive and resistant cell lines. the was to the of data in of the experiments to sites on 58 between the of sensitive and resistant cell a of The sites on of the sites or are in sensitive cell lines. sites are in resistant cell lines. dasatinib and Z. for quantitative protein in cell 2009; PubMed Scopus of of kinase PubMed Scopus we that in of the The of and between the sensitive and resistant the on the protein is and phosphorylation of the on which the was that the was of between sensitive and resistant protein protein kinase protein protein kinase kinase kinase protein protein protein kinase protein protein protein protein and protein protein and protein protein protein inhibitor protein protein A kinase protein kinase protein kinase protein of the on which the was that the was of between sensitive and resistant and protein in a new We or is in the of proteins The of proteins the of most From to in the study of PubMed Scopus the of is an of Many of the are on proteins involved in A that of the and the molecular are Many of to and or a of are protein and protein in the and protein and in the molecular a we the from phosphoproteomic to the phosphoproteomic in the A on proteins and in 2009; PubMed Scopus The as well as the of a the phosphorylation and the The that identified the most of the proteins in the sensitive The proteins involved in cell adhesion and cytoskeleton as and inhibitor protein integrin and the for a predictive was and was cross-validation on the cell data cell selection was to of the data and the We used a the for cancer selection PubMed Scopus for the used for the The of is in an cross-validation The used to a which was as the and to data cancer PubMed Scopus of of of PubMed Scopus signature predicting response and in breast cancer.J. Oncol. PubMed Scopus a that the between the as as possible The The 12 on The phosphorylation of the 12 identified sites the of sensitive and resistant cell of are in the sensitive cell lines. The show in The between the and are of the are on the same protein integrin or The is on the inhibitor protein we identified that are on the A the the protein the the inhibitor the protein and the protein the cross-validation was that the accurately and a A of PubMed Scopus well between sensitive and resistant cell selection is in which a of predictive the are to and the of is an of are and are The of to the in the is to the selection in the cross-validation a is on the data in the of only that the selection and tested the is to that the is used for the of for the Furthermore, the and the the would data are a in the quantitative of a in the of the to for the is used to the corresponding the selection of for is a in in a that the corresponding was is the in that from the a the was for the used for to The results as can from a of only cell was and and which to a of and an the of in the of cell cell used as A sensitive cell is the a and a resistant cell is the a The the to the the from in the the the can that of cell the the was only corresponding to the the in identifying a predictive the 12 the of the the was which further the of the of The sites are in and as a in for and for an of the 12 the results show that a predictive can identified from the the identified signature is specific to dasatinib or for to a to we the to the was only which is would predicting the a predictive signature for a we the of the the cell of cell lines. The to the from the and can as the in the is the is as sensitive The cell from to A of that the are the the between and of dasatinib is we to show the dasatinib signature is predictive for The is a inhibitor the and the growth The between the and of Li of non-small cell lung on 2009; PubMed Scopus is these results we that the identified is specific for predicting response to A and a of to in the in the data to is the to used for a in the of a is the selection of the cross-validation cross-validation in the data in the selection of we the in the selection for cancer selection PubMed Scopus to a in The of these for the 12 the of of was the 12 are in The to the an than and the 12 than of The of these is in the are the 12 in than of the and only in less than that the of cell effect on the label switch experiments cell and The results of the to these experiments are in of the the is to the data and and the of the the is the corresponding label switch is in study are in a and we the the is in the a that the of the signature in a and is likely to used the for can to data from targeted on or or targeted mass spectrometry as for quantitative A PubMed Scopus of targeted mass spectrometry for protein 2009; PubMed Scopus a is to targeted is to an We on that showed a the data of cell of the cell was sensitive or the phosphoproteomic is to for a of is a on a of proteins cell for The results of the protein data are in which that the is as as for the globally data the was the is to cancer we sensitive and resistant breast cancer cell lines. the and the of candidate molecular markers predicting in solid to for patient PubMed Scopus of the data and the six breast cancer cell to our for the cell the on the of cell lines. of the six breast cancer cell only resistant was to sensitive that the is predictive for dasatinib in cancer Four of the predictive on the protein we for and the of the or the is to between in the phosphorylation and in the of the corresponding in of is likely that the in the phosphorylation of the sites are in the of the protein that the of protein is in the of the cell we quantitative against the protein of and protein We as of the eight proteins for which only was identified as predictive is in cell and the of the cell to can in eight sensitive cell in only resistant cell is quantitative of experiments and The of the phosphorylation mass spectrometry The of most resistant cell are can in the sensitive cell lines. that of is predictive and that can used as marker of the of the in as resistant and eight sensitive cell would sensitive cell would as the of is as as the of the the for phosphorylation is We that the signature of 12 phosphorylation sites and the of is predictive in and breast cancer cell lines. is in cancer we of cancer The a PubMed Scopus the in cell and cancer a of of cancer an against protein of lung cancer are show to of six breast cancer are six show we show that the of can used as marker for The marker is in and is in a of of the cancer study that the of response markers from and quantitative experiments in a is of a of phosphorylation sites a panel of cancer cell is The of a of cell as a the of the The and of the phosphoproteomic was in label switch protein phosphorylation to and of kinase as and we that the basal of these allow predicting a response to therapy an We identified 58 that are between sensitive and resistant cell lines. of and as well as that of the proteins are involved in cell adhesion and cytoskeleton most are in the sensitive that dasatinib and of solid of the kinase of dasatinib and of PubMed Scopus and in cell and in on kinase for PubMed Scopus kinase inhibitor and cell and of and cell and non-small cell lung cancer PubMed Scopus which is of the of dasatinib Z. for quantitative protein in cell 2009; PubMed Scopus of of kinase PubMed Scopus We that in which to cell adhesion and cytoskeleton are to a is a of the is a the we the basal phosphoproteome of that are for to or of the kinase in the We showed that a of only 12 phosphorylation sites is sufficient to predict the response from the basal phosphoproteome of a The was on a We validated the of the in a cross-validation of cell The was and the the was The 12 phosphorylation sites on proteins and Four of the phosphorylation sites are on integrin or cell-matrix or cell-cell adhesion and are involved in to and cell The and the integrin is a for the of is to as the and phosphorylation of the integrin mediates to kinase and of PubMed Scopus of and A for PubMed Scopus A in the integrin for and PubMed Scopus Furthermore, of is patient in of integrin in breast is from of integrin in breast and PubMed Scopus The is and to the integrin to the A to protein PubMed Scopus the sites and in mass to our the for of the sites sites are in sensitive than in resistant to the integrin the signature eight on eight integrin β4, the inhibitor protein and the are involved in the as an a protein a protein The of and the of is an between and in the of PubMed Scopus A novel in kinase and in PubMed Scopus as for the and and of a novel PubMed Scopus a for and of cell and PubMed Scopus of and cell The inhibitor inhibitor of and the A protein are to the to and and and of PubMed Scopus the was to to the of and is a cell and a novel PubMed Scopus The is signature the same is in a proportion of cell lines. We is predictive of a response to to the of on and from in the PubMed Scopus six of sensitive and of cell a in the protein cell the effect is for we that from or is The that to dasatinib differ between and cell is the of is a of dasatinib sensitivity. on the a between the proteins protein protein protein and the dasatinib the that phosphorylation the response supports in the predictive From the is that of the signature proteins are to the proteins to the A on proteins and in 2009; PubMed Scopus we six signature proteins and proteins sites for most of the proteins in are less in the resistant cell than in the sensitive cell lines. The in phosphorylation of a specific between cell to a in of the corresponding the of phosphorylation of or a of The phosphoproteomic data allow between the as as the of a consistently between sensitive and resistant cell the for is for as a predictive of we show that protein is the protein of between sensitive and resistant cell lines. The study showed that the identified from a panel of cell can used in cancer cell lines. of six breast cancer cell resistant cell was to A markers for dasatinib in the or are in the of candidate molecular markers predicting in solid to for patient PubMed Scopus identified a predictive from the phosphorylation of the we the phosphorylation sites on the corresponding proteins are We phosphorylation sites on of the six and the phosphorylation to in sensitive cell and in resistant cell the is as as for the markers identified in of the sites are between the an sites on the the and as markers for dasatinib in experiments and in Z. and biomarkers in predict PubMed Scopus Z. and of a novel and for dasatinib a kinase PubMed Scopus of dasatinib in patients breast cancer biomarkers of to PubMed Scopus markers are and basal between sensitive and resistant we in the cell lines. We the phosphorylation of in cell to the of these cell lines. The on the protein was a was in cell and is between the sensitive and resistant and We our for the of a predictive in a of and breast cancer cell lines. The to a of the cell is from cell are experiments are and the can the signature or of the signature are predictive in to in of is possible to targeted as or the mass for quantitative in and 2009; PubMed Scopus allow the of marker of and can to of are the of our results to the the of and that the of proteins a that proteins can from and and that the proteins and are of and for and therapy in PubMed Scopus and are in and mass PubMed Scopus J.A. phosphorylation in cancer and targeted PubMed Scopus an we that the of can used as marker for The marker is in and is in a of of the cancer the phosphorylation data globally that the phosphoproteome is well between the cell lines. is to targeted of the We an the of eight that the of the is for the of the the identified of 12 phosphorylation sites is predictive for the to dasatinib in cell as well as breast cancer cell lines. The results that the of integrin as well as eight further proteins are candidate biomarkers for predicting response in solid to dasatinib and to kinase of the signature proteins and are in a further supports the of the predictive study we a for identifying response biomarkers on a phosphorylation The is as the phosphorylation sites to and the of of the to The of the is the quantitative phosphoproteomic of we that the identifying a predictive phosphorylation signature for response to dasatinib in cell can that the can to kinase and to We are to for and We for in the cell as well as and the for for cell lines.